Last $5.29 USD
Change Today -0.02 / -0.38%
Volume 939.9K
CERS On Other Exchanges
Symbol
Exchange
CERS is not on other exchanges.
As of 8:10 PM 01/23/15 All times are local (Market data is delayed by at least 15 minutes).

cerus corp (CERS) Snapshot

Open
$5.28
Previous Close
$5.31
Day High
$5.35
Day Low
$5.13
52 Week High
02/25/14 - $8.00
52 Week Low
07/28/14 - $3.48
Market Cap
475.8M
Average Volume 10 Days
1.5M
EPS TTM
$-0.38
Shares Outstanding
89.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CERUS CORP (CERS)

cerus corp (CERS) Related Bloomberg News

View More Bloomberg News

cerus corp (CERS) Related Businessweek News

No Related Businessweek News Found

cerus corp (CERS) Details

Cerus Corporation, together with its subsidiary, Cerus Europe B.V., operates as a biomedical products company in Europe, the Commonwealth of Independent States, and the Middle East. The company develops and commercializes the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication and designed to target and inactivate blood-borne pathogens, including viruses, bacteria, and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. The company’s INTERCEPT Blood System for platelets is designed to inactivate blood-borne pathogens in platelets donated for transfusion; INTERCEPT Blood System for plasma is designed to inactivate blood-borne pathogens in plasma donated for transfusion; and INTERCEPT Blood System for red blood cells is designed to inactivate blood-borne pathogens in red blood cells donated for transfusion. Cerus Corporation markets its platelet and plasma systems through its direct sales force and distributors. The company has collaboration agreements with Baxter International, Inc. for the development and commercialization of the INTERCEPT Blood System. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.

115 Employees
Last Reported Date: 03/7/14
Founded in 1991

cerus corp (CERS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $495.8K
Co-Founder, Chief Medical Officer, Chief Scie...
Total Annual Compensation: $398.2K
Chief Financial Officer and Vice President of...
Total Annual Compensation: $277.0K
President of Cerus Europe and EEMEA
Total Annual Compensation: $304.4K
Senior Vice President of Regulatory Affairs, ...
Total Annual Compensation: $315.4K
Compensation as of Fiscal Year 2013.

cerus corp (CERS) Key Developments

Cerus Corporation Reports EU Phase 3 Clinical Trial of INTERCEPT Red Blood Cells Met Primary Endpoint

Cerus Corporation announced that its European Phase 3 clinical trial of red blood cells treated with the INTERCEPT Blood System for acute anemia in cardiovascular surgery patients met the primary endpoint. Preliminary analysis demonstrated that the mean hemoglobin content (53.1g) of INTERCEPT-treated red blood cell components (RBCs) on day 35 of storage met the protocol-defined criteria for equivalence based on the inferiority margin of 5g compared to conventional red blood cell components (55.8g). The investigators plan to submit data from the study for presentation at upcoming scientific congresses. The randomized, double-blind, controlled, multi-center Phase 3 clinical trial of the INTERCEPT red blood cell system evaluated the efficacy of the INTERCEPT System to process RBCs with quality and mean hemoglobin content (>40 g) suitable to support transfusion according to the European Directorate for the Quality of Medicines (EDQM). The blood components were transfused to 51 cardiovascular surgery patients at two German clinical trial sites to evaluate transfusion efficacy and overall safety. Patients undergoing procedures for either coronary artery bypass grafting (CABG), valve repair or combined procedures received study transfusions during a 7-day treatment period that included the day of surgery and 6 days post-operatively. The patients received either INTERCEPT-treated RBCs or control RBCs not treated for pathogen inactivation. Red blood cell components for both clinical sites were manufactured at the German Red Cross blood center in Frankfurt, and the study RBCs were stored for up to 35 days prior to transfusion. The primary endpoint of equivalence of mean hemoglobin content between INTERCEPT RBCs and conventional RBCs was met within the protocol specified 5g equivalence margin based on over 750 study RBC components manufactured. The secondary efficacy endpoints also demonstrated suitability for transfusion based on mean hematocrit of 60.4% (acceptance range: 55-70%) and mean end of storage hemolysis of 0.28% (acceptance range < 0.8%). There were no statistical differences in the adverse event rates between recipients of INTERCEPT treated and control RBCs. There were no clinically relevant trends in severe or serious treatment related adverse events by system organ class. The observed adverse events were within the expected spectrum of co-morbidity and mortality for patients of similar age and with advanced cardiovascular diseases undergoing cardiovascular surgery requiring red cell transfusion. No patients exhibited an immune response to INTERCEPT treated RBCs. The INTERCEPT red cell system is being developed to improve blood transfusion safety due to risks of transfusion transmitted infections (TTIs) and may have the additional benefits of enhanced safety with respect to transfusion-associated graft versus host disease (TA-GVHD), with the possibility of enhanced RBC viability compared to gamma irradiated RBC components. S-303 treated RBCs contain much less plasma than conventional RBC components, and thus offer the potential for reduced plasma-mediated allergic reactions and transfusion-related acute lung injury (TRALI).

Cerus Corporation Reports US Phase 2 Clinical Trial of INTERCEPT Red Blood Cells Met Primary Endpoint

Cerus Corporation announced that its Phase 2 clinical trial of red blood cells treated with the INTERCEPT Blood System met its primary endpoint, with preliminary analysis demonstrating that greater than 75% of treated red blood cells continued to circulate 24 hours following transfusion. The investigators plan to submit data from the study for presentation at an upcoming scientific congress. The randomized, single-blind, controlled, multi-center Phase 2 clinical trial of the INTERCEPT red blood cell system evaluated 26 healthy subjects at two United States clinical trial sites. Each subject received two transfusions of the subject's own red blood cells, one INTERCEPT-treated, and the other a control not treated for pathogen inactivation. Red blood cell units were stored for 35 days prior to transfusion. The primary endpoint of the clinical trial, a mean INTERCEPT red blood cell recovery of greater than 75% at 24 hours post-transfusion, was met. The INTERCEPT red blood cells had a recovery of 83% compared to 85% for control red blood cells, and both INTERCEPT-treated and control red blood cells met the criteria for red blood cell recovery recommended by the U.S. Food and Drug Administration. In Europe, Cerus recently completed a Phase 3 clinical study of the INTERCEPT red blood cell system in patients with acute anemia and plans to file for CE mark approval.

Cerus Corporation - Special Call

To discuss the U.S. approval for INTERCEPT platelets

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CERS:US $5.29 USD -0.02

CERS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Antares Pharma Inc $2.35 USD +0.02
AtriCure Inc $20.22 USD +0.35
Biolase Inc $2.63 USD +0.05
STAAR Surgical Co $7.17 USD 0.00
SurModics Inc $22.06 USD -0.21
View Industry Companies
 

Industry Analysis

CERS

Industry Average

Valuation CERS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 11.0x
Price/Book 8.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 11.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CERUS CORP, please visit www.cerus.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.